In a recent bid Akebia Therapeutics Inc. [AKBA] faced a contemporary bid of $3.58 yielding a 26.95% incline where 9.51 million shares have exchanged hands over the last week. AKBA amount got a boost by 0.85% or $0.03 versus $3.55 at the end of the prior session. This change led market cap to move at 479.68M, putting the price 52.99% below the 52-week high and -73.89% above the 52-week low. The company’s stock has a normal trading capacity of 9.51 million shares while the relative volume is 1.74.
On 9, October 2020, Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined. According to news published on Yahoo Finance, – Phase 3 data from INNO2VATE program in dialysis and PRO2TECT program in non-dialysis accepted for oral presentation.
Analyst Birdseye View:
The most recent analyst activity for Akebia Therapeutics Inc. [NASDAQ:AKBA] stock was on August 06, 2019, when it was Reiterated with a Buy rating from H.C. Wainwright, which also lowered its 12-month price target on the stock from $19 to $17. Before that, on November 14, 2019, Needham Recapitulated a Buy rating and elevated its amount target to $15. On July 11, 2019, H.C. Wainwright Reiterated a Buy rating and plunged its price target on this stock from $23 to $21. On May 02, 2019, JP Morgan Initiated an Overweight rating and increased its price target to $12. On March 20, 2019, Citigroup Initiated a Neutral rating and increased its price target to $9. On September 07, 2018, Morgan Stanley Resumed an Equal-weight rating. On August 10, 2018, Needham Reiterated a Buy rating and decreased its target amount on this stock from $20 to $18. On June 06, 2018, H.C. Wainwright Reiterated a Buy rating and improved its amount target to $22.
In the past 52 weeks of trading, this stock has oscillated between a low of $2.34 and a peak of $13.71. Right now, the middling Wall Street analyst 12-month amount mark is $6.00. At the most recent market close, shares of Akebia Therapeutics Inc. [NASDAQ:AKBA] were valued at $3.58.
Akebia Therapeutics Inc. [NASDAQ:AKBA] most recently reported quarterly sales of 90.14 billion, which represented growth of -10.60%. This publicly-traded organization’s revenue is $930,558 per employee, while its income is -$776,831 per employee. This company’s Gross Margin is currently 61.70%, its Pretax Margin is -85.46, and its Net Margin is -83.48. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -29.74, -54.27, -49.62 and -49.32 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 21.53 and the whole liability to whole assets at 14.05. It shows enduring liability to the whole principal at 20.54 and enduring liability to assets at 0.13 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 3.40 points at 1st support level, the second support level is making up to 3.23. But as of 1st resistance point, this stock is sitting at 3.71 and at 3.85 for 2nd resistance point.
Akebia Therapeutics Inc. [AKBA] reported its earnings at -$1.28 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.5/share signifying the difference of -0.78 and -156.00% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.47 calling estimates for -$0.62/share with the difference of 0.15 depicting the surprise of 24.20%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Akebia Therapeutics Inc. [NASDAQ:AKBA] is 2.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 0.71. Now if looking for a valuation of this stock’s amount to sales ratio it’s 2.23 and it’s amount to book ratio is 1.95.
The most recent insider trade was by GOWEN MAXINE, Director, and it was the sale of 4567.0 shares on Jun 08. GILMAN STEVEN C, the Director, completed a sale of 4567.0 shares on Jun 08. On Jun 08, Smith Cynthia, Director, completed a sale of 4567.0 shares.